MARKET

RARE

RARE

Ultragenyx Pharm
NASDAQ
30.77
+1.52
+5.20%
After Hours: 30.77 0 0.00% 18:54 06/26 EDT
OPEN
29.39
PREV CLOSE
29.25
HIGH
30.99
LOW
29.36
VOLUME
17.18M
TURNOVER
--
52 WEEK HIGH
42.37
52 WEEK LOW
18.29
MARKET CAP
3.03B
P/E (TTM)
-5.0423
1D
5D
1M
3M
1Y
5Y
1D
Calidi Biotherapeutics Appoints Former Celgene Executive Corsee Sander To Board Of Directors
NASDAQ · 3d ago
CALIDI BIOTHERAPEUTICS APPOINTS FORMER GENENTECH/ROCHE AND CELGENE EXECUTIVE CORSEE SANDERS, PH.D., TO BOARD OF DIRECTORS
Reuters · 4d ago
Spruce Biosciences names Agnieszka Jurecka vice president, medical affairs
PUBT · 5d ago
Weekly Report: what happened at RARE last week (0615-0619)?
Weekly Report · 5d ago
Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity
Seeking Alpha · 6d ago
Ultragenyx grants 44,409 RSUs to 15 new hires under inducement plan
PUBT · 06/19 20:30
ULTRAGENYX REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/19 20:30
Press Release: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 06/19 20:30
More
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH.

Webull offers Ultragenyx Pharmaceutical Inc stock information, including NASDAQ: RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.